News

Filter

Current filters:

VyvanseGenerics

Sandoz files for generic of Shire’s Vyvanse; FDA warning

20-05-2011

Ireland-headquartered biopharmaceutical company Shire (LSE: SHP) yesterday revealed that its US subsidiary…

GenericsMarkets & MarketingNeurologicalNorth AmericaNovartisPatentsPharmaceuticalRegulationSandozShireVyvanse

Generic erosion will see ADHD drug market fall from $5 billion in 2009 to $4.1 billion in 2019

07-12-2010

The attention-deficit hyperactivity disorder (ADHD) drug market in the top seven countries (the USA,…

AdderallGenericsIntunivMarkets & MarketingNeurologicalPharmaceuticalShireVyvanse

US Court upholds FDA’s grant of five-year market exclusivity for Shire’s ADHD drug Vyvanse

05-03-2010

The US District Court for the District of Columbia has upheld the Food and Drug Administration’s…

Genericslisdexamfetamine dimesylateNeurologicalNorth AmericaPatentsPharmaceuticalRegulationShireVyvanse

US FDA says Shire’s Vyvanse was properly granted five-year market exclusivity

26-10-2009

The US Food and Drug Administration, following a thorough administrative review of governing statutory…

GenericsGlaxoSmithKlineGSKlisdexamfetamine dimesylateNeurologicalNorth AmericaPatentsPharmaceuticalShireVyvanse

Back to top